Pirfenidone (PRF) is a synthetic compound used to treat idiopathic pulmonary fibrosis, but its oral administration may cause systemic side effects. This study aimed to develop and validate a bioanalytical method to quantify PRF and evaluate the pharmacokinetic and biodistribution profile of PRF-loaded solid lipid nanoparticles (SLNs) delivered via the pulmonary route. A high-performance liquid chromatography (HPLC) method was validated following the Food and Drug Administration (FDA) guidelines, showing acceptable selectivity, accuracy, precision, and stability in plasma and lung tissue. PRF SLNs were prepared by solvent injection and had a mean particle size of 240.3 ± 3.57 nm and a polydispersity index of 0.386–0.392. Intratracheal administration of PRF SLNs resulted in higher maximum concentration and Area Under the Curve (AUC) values than oral PRF. Biodistribution studies showed that PRF SLNs achieved approximately fivefold greater AUC in lung tissue than free PRF, with lower distribution in the liver and kidneys. These findings indicate that pulmonary PRF SLNs enhance lung targeting and may reduce systemic exposure, while the validated HPLC method supports reliable pharmacokinetic and tissue distribution analysis.
Putri SA, Harahap Y , Surini S. Bioanalytical method development and validation for the pharmacokinetics and biodistribution study of pirfenidone loaded solid lipid nanoparticles. J Appl Pharm Sci. 2025. Article in Press. http://doi.org/10.7324/JAPS.2026.231524
1. Hazem RM, Antar SA, Nafea YK, Al-Karmalawy AA, Saleh MA, ElAzab MF. Pirfenidone and vitamin D mitigate renal fibrosis induced by doxorubicin in mice with Ehrlich solid tumor. Life Sci. 2022;288:120185. doi: https://doi.org/10.1016/j.lfs.2021.120185
2. Ruwanpura SM, Thomas BJ, Bardin PG. Pirfenidone: molecular mechanisms and potential clinical applications in lung disease. Am J Respir Cell Mol Biol. 2020;62:413–22. https://doi.org/10.1165/rcmb.2019-0328TR
3. Barranco-Garduño LM, Buendía-Roldan I, Rodriguez JJ, González-Ramírez R, Cervantes-Nevárez AN, Neri-Salvador JC, et al. Pharmacokinetic evaluation of two pirfenidone formulations in patients with idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis. Heliyon. 2020;6:e05279. doi: https://doi.org/10.1016/j.heliyon.2020.e05279
4. Shi C, Ignjatovi? J, Wang J, Guo Y, Zhang L, Cviji? S, et al. Evaluating the pharmacokinetics of intrapulmonary administered ciprofloxacin solution for respiratory infections using in vivo and in silico PBPK rat model studies. Chin Chem Lett. 2023;34:107463. doi: https://doi.org/10.1016/j.cclet.2022.04.061
5. Weber S, Zimmer A, Pardeike J.Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for pulmonary application. Eur J Pharm Biopharm. 2014;86:7–22. https://doi.org/10.1016/j.ejpb.2013.08.013
6. Kwok K, Suhariyono G, Surini S. Response surface methodology-aided development of pirfenidone-loaded solid lipid nanoparticles for intrapulmonary drug delivery system. Int J Appl Pharm. 2024;16:283–90. https://doi.org/10.22159/ijap.2024v16i4.50231
7. Cheruku S, Darna B, Medipalli V, Nekkalapudi AR, Sadasivam RK. Bioanalytical method development and validation for the quantitation of larotrectinib in human plasma: application to pharmacokinetics in healthy rabbits. J Appl Pharm Sci. 2023;13:111–8. https://doi.org/10.7324/JAPS.2023.127799
8. Food and Drug Administration (FDA), Center for drug evaluation and research. Bioanalytical method validation: guidance for industry. Silver Spring, MD: Food and Drug Admnistration, 2018.
9. Meng H, Xu Y. Pirfenidone-loaded liposomes for lung targeting: preparation and in vitro/in vivo evaluation. Drug Des Devel Ther. 2015;9:3369–76. https://doi.org/10.2147/DDDT.S84046
10. Togami K, Kanehira Y, Tada H. Pharmacokinetic evaluation of tissue distribution of pirfenidone and its metabolites for idiopathic pulmonary fibrosis therapy. Biopharm Drug Dispos. 2015;36:205–15. https://doi.org/10.1002/bdd.1932
11. Harahap Y, Saputra R, Kuswardani. Development and validation of methamphetamine analysis methods in dried blood spot sample using gas chromatography - mass spectrometry. Int Res J Pharm. 2019;10:18–24. https://doi.org/10.7897/2230-8407.1008240
12. Kang JH, Yang MS, Kim DW, Park CW. In vivo pharmacokinetic and pharmacodynamic study of co-spray-dried inhalable pirfenidone microparticles in rats. Drug Deliv. 2022;29:3384–96. https://doi.org/10.1080/10717544.2022.2149899
13. Huang Z, Huang Y, Wang W, Fu F, Wang W, Dang S, et al. Relationship between particle size and lung retention time of intact solid lipid nanoparticle suspensions after pulmonary delivery. J Control Release. 2020;325:206–22. https://doi.org/10.1016/j.jconrel.2020.06.004
14. Chaurasiya B, Zhao YY. Dry powder for pulmonary delivery: a comprehensive review. Pharmaceutics. 2021;13:1–28. https://doi.org/10.3390/pharmaceutics13010031
15. Maboos M, Yousuf RI, Shoaib MH, Nasiri I, Hussain T, Ahmed HF, et al. Effect of lipid and cellulose based matrix former on the release of highly soluble drug from extruded/spheronized, sintered and compacted pellets. Lipids Health Dis. 2018;17:136. doi: https://doi.org/10.1186/s12944-018-0783-8
16. Price DN, Stromberg LR, Kunda NK, Muttil P. In vivo pulmonary delivery and magnetic-targeting of dry powder nano-in-microparticles. Mol Pharm. 2017;14:4741–50. https://doi.org/10.1021/acs.molpharmaceut.7b00532
17. Magramane S, Pápay Z, Turbucz B, Antal I. Formulation and characterization of pulmonary drug delivery systems. Acta Pharm Hung. 2019;89:63–83. https://doi.org/10.33892/aph.2019.89.63-83
18. Huang L, Huang XH, Yang X, Hu JQ, Zhu YZ, Yan PY, et al. Novel nano- drug delivery system for natural products and their application. Pharmacol Res. 2024;201:107100. doi: https://doi.org/10.1016/j.phrs.2024.107100
19. He Y, Liang Y, Mak JCW, Liao Y, Li T, Yan R, et al. Size effect of curcumin nanocrystals on dissolution, airway mucosa penetration, lung tissue distribution and absorption by pulmonary delivery. Colloids Surf B Biointerfaces. 2020;186:110703. doi: https://doi.org/10.1016/j.colsurfb.2019.110703
20. Nemmar A, Al-Salam S, Beegam S, Yuvaraju P, Ali BH. The acute pulmonary and thrombotic effects of cerium oxide nanoparticles after intratracheal instillation in mice. Int J Nanomed. 2017;12:2913–22. https://doi.org/10.2147/IJN.S127180
21. Schneider CS, Xu Q, Boylan NJ, Chisholm J, Tang BC, Schuster BS, et al. Nanoparticles that do not adhere to mucus provide uniform and long-lasting drug delivery to airways following inhalation. 2017;3(4):e1601556. doi: https://doi.org/10.1126/sciadv.1601556
Year
Month